CMS Will Focus On Value, Not Price, Of Medicines, McClellan Pledges
Executive Summary
Medicare reimbursement should be based on the "value" of medicines, not their price, incoming Centers for Medicare & Medicaid Services Administrator Mark McClellan told the Senate Finance Committee in a 1written Q&A exchange
You may also be interested in...
Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling
Kaiser Permanente is developing a clinical trials modeling tool that can also be used to estimate a drug's cost-effectiveness
Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling
Kaiser Permanente is developing a clinical trials modeling tool that can also be used to estimate a drug's cost-effectiveness
CMS Says Medicare Rx Will Grow 7.5% Per Year; Challenge To Pharma?
The rate of per capita drug spending under the new Medicare Part D benefit will be half the current rate of prescription drug spending growth in the U.S., CMS predicts